Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $91
Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and lowers the price target from $95 to $91.
Barclays Upgrades Xcel Energy to Overweight, Raises Price Target to $76
Barclays analyst Eric Beaumont upgrades Xcel Energy (NASDAQ:XEL) from Equal-Weight to Overweight and raises the price target from $75 to $76.
Barclays Upgrades Five9 to Overweight, Announces $206 Price Target
Barclays analyst Raimo Lenschow upgrades Five9 (NASDAQ:FIVN) from Equal-Weight to Overweight and announces $206 price target.
Barclays Upgrades CenterPoint Energy to Overweight, Raises Price Target to $30
Barclays analyst Eric Beaumont upgrades CenterPoint Energy (NYSE:CNP) from Equal-Weight to Overweight and raises the price target from $28 to $30.
Wells Fargo Upgrades Five9 to Overweight, Announces $200 Price Target
Wells Fargo analyst Michael Turrin upgrades Five9 (NASDAQ:FIVN) from Equal-Weight to Overweight and announces $200 price target.
Canaccord Genuity Upgrades Five9 to Buy
Canaccord Genuity analyst David Hynes upgrades Five9 (NASDAQ:FIVN) from Hold to Buy.
Morgan Stanley Upgrades Zuora to Equal-Weight, Announces $18 Price Target
Morgan Stanley analyst Stan Zlotsky upgrades Zuora (NYSE:ZUO) from Underweight to Equal-Weight and announces $18 price target.
Citigroup Upgrades General Mills to Buy, Raises Price Target to $70
Citigroup analyst Wendy Nicholson upgrades General Mills (NYSE:GIS) from Neutral to Buy and raises the price target from $63 to $70.
Jefferies Maintains Buy on Ares Management, Raises Price Target to $86
Jefferies analyst Gerald O'Hara maintains Ares Management (NYSE:ARES) with a Buy and raises the price target from $82 to $86.
Aegis Capital Maintains Buy on Kintara Therapeutics, Lowers Price Target to $5
Aegis Capital analyst Nathan Weinstein maintains Kintara Therapeutics (NASDAQ:KTRA) with a Buy and lowers the price target from $7 to $5.